Safety and tolerability of long lasting LDL-apheresis in familial hyperlipoproteinemia

被引:20
作者
Blaha, Milan
Cermanova, Melanie
Blaha, Vladimir
Blazek, Martin
Maly, Jaroslav
Siroky, Oldrich
Solichova, Dagmar
Filip, Stanislav
Rehacek, Vit
机构
[1] Charles Univ Prague, Fac Hosp, Internal Clin 2, Dept Haematol, Hradec Kralove, Czech Republic
[2] Charles Univ Prague, Fac Hosp, Clin Metab Care & Gerontol, Hradec Kralove, Czech Republic
[3] Charles Univ Prague, Fac Hosp, Clin Radiol & Oncol, Hradec Kralove, Czech Republic
[4] Charles Univ Prague, Fac Hosp, Dept Blood Transfus, Hradec Kralove, Czech Republic
关键词
adverse events; atherosclerosis; familial hyperlipoproteinemia; LDL-apheresis; side-effects; DENSITY-LIPOPROTEIN PRECIPITATION; THERAPY;
D O I
10.1111/j.1744-9987.2007.00450.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aim of this work is to arbitrate the incidence of side effects and tolerability of long lasting LDL-apheresis in familial hyperlipoproteinemia. 1200 procedures were performed and the last 463 of them were evaluated. An immunoadsorption method of LDL-apheresis was used (continuous blood cell separator Cobe Spectra; secondary device: automated adsorption-desorption ADA, Medicap; absorption columns: Lipopak). As a whole, 6.26% adverse events were found and subsequently resolved by standard symptomatic therapy. Vaso-vagal reactions (symptoms of neurovegetative lability) were the most common adverse effects, presented as malaise, weakness, slight and short-term drop in blood pressure or other general signs. They were all well controlled by symptomatic therapy. We conclude that LDL-apheresis in the hands of experienced personnel is a safe procedure. An acceptable procedure duration limit, balancing the possibility to achieve a targeted cholesterol level while still maintaining an acceptable patient tolerance, was confirmed to be 4 hours.
引用
收藏
页码:9 / 15
页数:7
相关论文
共 22 条
[1]   Is lipoprotein (a)-apheresis useful? [J].
Bambauer, R .
THERAPEUTIC APHERESIS AND DIALYSIS, 2005, 9 (02) :142-147
[2]   Low-density lipoprotein apheresis: An overview [J].
Bambauer, R ;
Schiel, R ;
Latza, R .
THERAPEUTIC APHERESIS AND DIALYSIS, 2003, 7 (04) :382-390
[3]   Optimization of the therapeutic procedure during LDL-apheresis - a computerized model [J].
Blaha, M ;
Masin, V ;
Stransky, P ;
Blaha, V ;
Cermanova, M ;
Maly, J ;
Belada, D .
TRANSFUSION AND APHERESIS SCIENCE, 2005, 32 (02) :149-156
[4]  
BLAHA M, 2002, ACTA MED HRADEC KRAL, V45, P48
[5]  
BLAHA M, 1995, MULTIPLE MYELOMA PAR, P121
[6]  
Blaha V, 1998, Cas Lek Cesk, V137, P424
[7]  
BLAHA V, 2001, KAPITOLY KARDIOLOGIE, V3, P72
[8]  
BLAHA V, 2001, NUTR METABOLIC SUPPO, P159
[9]   Heparin-mediated extracorporeal low-density lipoprotein precipitation: rationale for a specific adjuvant therapy in cardiovascular disease [J].
Blessing, F ;
Wang, Y ;
Walli, AK ;
Seidel, D .
TRANSFUSION AND APHERESIS SCIENCE, 2004, 30 (03) :255-266
[10]   The efficacy and safety of the new heparin-induced extracorporeal low-density lipoprotein precipitation system (Plasmat Futura) in comparison with the currently used system (Plasmat Secura) [J].
Blessing, F ;
Wang, Y ;
Nagel, D ;
Seidel, D .
THERAPEUTIC APHERESIS AND DIALYSIS, 2004, 8 (01) :33-38